Literature DB >> 2086386

Iron metabolism in thalassemia intermedia.

G Fiorelli1, S Fargion, A Piperno, N Battafarano, M D Cappellini.   

Abstract

Iron overload is frequently present in patients with thalassemia intermedia, and it becomes evident mainly after the second and third decades of life. The degree of the iron load is heterogeneous ranging from mild to severe. In this study we evaluated the iron status of 38 adult patients with thalassemia intermedia and we looked for factors possibly related to the observed heterogeneity of the iron status. The levels of transferrin saturation (TS), serum ferritin (SF) and desferrioxamine-induced urinary iron excretion (DFU) were spread in a wide range from normal to markedly increased. These indices did not correlate with other parameters such as age, hemoglobin levels and entity of the erythropoietic status. A significant difference in the degree of iron overload was observed between patients who underwent splenectomy and non-splenectomized patients. TS, SF and DFU were significantly higher in splenectomized than in non- splenectomized patients, indicating that the spleen could have a role in the regulation of iron metabolism in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2086386

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

Review 1.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

Review 2.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

3.  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors:  Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

4.  Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.

Authors:  Adisak Tantiworawit; Pimlak Charoenkwan; Sasinee Hantrakool; Worawut Choeyprasert; Chate Sivasomboon; Torpong Sanguansermsri
Journal:  Int J Hematol       Date:  2016-04-06       Impact factor: 2.490

Review 5.  β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Authors:  Yelena Ginzburg; Stefano Rivella
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

6.  Serum ferritin in thalassemia intermedia.

Authors:  Ravi Shah; Amita Trehan; Reena Das; R K Marwaha
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-06       Impact factor: 0.900

7.  Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.

Authors:  Brian C Beard; Grant D Trobridge; Christina Ironside; Jeannine S McCune; Jennifer E Adair; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

Review 8.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

Review 9.  Ineffective erythropoiesis and thalassemias.

Authors:  Stefano Rivella
Journal:  Curr Opin Hematol       Date:  2009-05       Impact factor: 3.284

Review 10.  Intestinal calcium transport and its regulation in thalassemia: interaction between calcium and iron metabolism.

Authors:  Kornkamon Lertsuwan; Kannikar Wongdee; Jarinthorn Teerapornpuntakit; Narattaphol Charoenphandhu
Journal:  J Physiol Sci       Date:  2018-02-26       Impact factor: 2.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.